Introduction: The translocator protein (18 kDa) (TSPO) is widely expressed in peripheral tissues, including the heart, lung, and kidney. Our laboratory developed N-benzyl-N-methyl-2[7,8-dihydro-7-(2-[F-18]fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide ([F-18]FEDAC) as a TSPO positron emission tomography (PET) ligand. Here, using small-animal PET with [F-18]FEDAC, we performed TSPO imaging and quantitative analysis of TSPO binding in rat peripheral tissues.
Methods: The in vivo distribution and kinetics of [F-18]FEDAC were measured in rat peripheral tissues (heart, lung and kidney). Using the in vivo pseudo-equilibrium method, TSPO binding parameters [TSPO density (B-max), dissociation constant (K-D)] and receptor occupancy were estimated in these peripheral tissues.
Results: [F-18]FEDAC was highly distributed in the lung, heart and kidney, and these TSPO-enriched tissues could be clearly visualized. The kinetics of this radioligand in these tissues was rapid, which is suitable for the determination of in vivo TSPO binding parameters and receptor occupancy. The B-max value of TSPO in the heart, lung, and kidney was 393, 141, and 158 pmol/ml, respectively. The K-D value of the radioligand in the heart, lung, and kidney was 119, 36 and 123 nM, respectively. By pretreatment with 5 mg/kg Ro 5-4864 (a TSPO ligand), about 90% of binding sites for TSPO in the heart and lung were occupied. In the kidney, the binding sites were completely occupied by 5 mg/kg Ro 5-4864.
Conclusions: [F-18]FEDAC is a suitable PET ligand for TSPO imaging and quantitative analysis of TSPO binding in rat peripheral tissues. The utilization of [F-18]FEDAC-PET and the pseudo-equilibrium method can contribute to the study of the TSPO function and evaluate the in vivo binding parameters and receptor occupancy of TSPO therapeutic compounds. (C) 2010 Elsevier Inc. All rights reserved.